Pancreatic Cancer Research

ResearcherXijing HospitalNo recent work listed

Xin Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9658-1887; OpenAlex author ID A5101839804. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 4

  1. KCNN4-mediated Ca2+/MET/AKT axis is promising for targeted therapy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41401-021-00688-3↗
  2. Dysbindin promotes pancreatic ductal adenocarcinoma metastasis by activating NF-κB/MDM2 via miR-342-3p. Co-author DOI 10.1016/j.canlet.2020.02.033↗
  3. Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K. First author DOI 10.1093/jmcb/mjx043↗
  4. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling. Co-author DOI 10.1002/ijc.30227↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alaa Abdelatty · 1 shared paper, 2022 · strength 0.13
  2. Hongping Xia · 1 shared paper, 2022 · strength 0.13
  3. Xiao Mo · 1 shared paper, 2022 · strength 0.13
  4. Cheng Fang · 2 shared papers, 2016–2017 · strength 0.12
  5. Yong Chen · 2 shared papers, 2016–2017 · strength 0.12
  6. Dinghuang Zhu · 1 shared paper, 2020 · strength 0.10
  7. Ning Xie · 1 shared paper, 2020 · strength 0.10
  8. Yong Chen · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.